Amylin/Lilly: Resurrections and Conversions

Resurrections are an old biotech story. Now it's Amylin's happy duty to play the leading role--thanks to a product surprise. Its best known product, Symlin, delayed in the clinic, looks to be a smaller market product for diabetes than AC2993, which could compete with oral medicines. Lilly's signed up for a major deal on the product when its own competitive program failed. The deal itself gets Amylin a true partner's interest in the development and commercial prospects for the drug, but includes some interesting convertibility features that put Amylin at some risk if it doesn't perform.

Resurrections are an old biotech story. Now it's Amylin Pharmaceuticals Inc. 's happy duty to play the leading role, thanks to a product surprise.

By 1998, the company's leading product, pramlintide (Symlin), had twice failed to show efficacy in clinical trials. It was unceremoniously...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.